Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Now 45p - please someone explain this to me!!!!
RB did you get back in at around 44p? If so you must be smiling now!!
Mmm. R&D costs down - no surprise as Flu-V is sat on the shelf and they have cancelled discovery stage projects.
Why are they only now going to speak to FDA and EMEA about Flu-V- more than a year after generating the Ph2b data, amazing?? There is obviously something putting off potential acquirers/partners.
I would guess that GSK's change in strategy was partly to blame for contract cancellations and agree an RNS would have been nice to inform us of these.
£2.4m R&D tax credit adds to the coffers but this will be significantly less next year, given the reduced R&D spend.
At least the BOD sees the company remaining as a 'going concern' for the next 12 months - small mercy's!!
Woodford get the wool pulled over his eyes....never! I think one strategy we should all have followed was to avoid anything Woodford put money into. Hindsight is a .......
I am an eternal optimist but even I am losing the will here. I am in the Biotech industry and, inmho, if anyone was going to acquire or partner for FLu-V it would have happened by now. Big pharma would have been all over this a year or more ago and whilst these deals can take time they can also be completed in a matter of weeks. ADYOR.
Mark, yes I know about drug dev timelines - been in the industry for over 30 years - but this is worrying. To have a potential blockbuster asset sat on the shelf doing nothing for 12 months is quite honestly ridiculous.
They may not run out of cash but they have nowhere near what is required to fund a Ph3 program. I for one would like an update on progress re negotiations for sale of the asset or for raising funds to undertake its future development.
Agreed Mon. One year post Ph2b results with no apparent activity is not a good sign whatsiever. BOD absolutely need to make some statement especially with the share price essentially at a 5year low!
I think we are all in the same boat! Unfortunately I am in a number of shares that Woodford is in and also hold shares in the Woodford Patient Capital Trust, for which I am now well down on as well.
I think its time for a holiday!!
Does appear that a number of shares that are included in Woodfords Funds are suffering in the aftermath of todays announcement.
What would certainly help here would be anything positive from the BOD - nearly a year now since the Flu-V Ph2 results were announced. Broken record ... I know, but at least let us know you are still alive and kicking.
RBT - I think we are on exactly the same page.
Postings here have been very entertaining this afternoon, certainly brightened up my day!!
Pity we slipped back again but as has been said - Friday before a long weekend.....However, I think we are in a good position for when the markets open on Tuesday.
RBT, I agree that people should focus on the fact that the DOJ are 'claiming' that the safety claims made by Ind are not supported by clinical data and therefore promoting on that safety data is illegal. Ind are not contributing to the opioid crisis.
BTW, I am also a scientist and the CEO of a British biotech company (privately owned)!!
Agreed Jimzi !
And Head - I have been in drug development at senior levels for over 30years and as such am fully aware when progress is painfully slow. Flu-v should have entered Ph3 pivotal studies a year ago - at the end of the day no progress is no progress and hence Mon and I taking a tongue in cheek swipe at HVO!
ATB